New Studies Presented at the International Society for Health Economics and Outcomes Research Meeting (ISPOR 24) Show Growing Burden and Impact of Generalized Anxiety Disorder (GAD) in the US

Contributed by: Business Wire

Logo

Business Wire logo

Images

Figure 1. Work Productivity: Absenteeism, presenteeism, overall work productivity loss and activity impairment: GAD by symptom severity vs. controls. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with controls are marked with asterisks. Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay. Absenteeism was not calculated for those who worked 0 hours and missed 0 hours in the last 7 days, and presenteeism was only asked among those who worked >0 hours in the last 7 days. (Abbreviations: GAD: generalized anxiety disorder.) (Graphic: Business Wire)
Figure 1. Work Productivity: Absenteeism, presenteeism, overall work productivity loss and activity impairment: GAD by symptom severity vs. controls. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with controls are marked with asterisks. Absenteeism, Presenteeism, and Overall work impairment were only applicable to those indicating they were currently working for pay. Absenteeism was not calculated for those who worked 0 hours and missed 0 hours in the last 7 days, and presenteeism was only asked among those who worked >0 hours in the last 7 days. (Abbreviations: GAD: generalized anxiety disorder.) (Graphic: Business Wire)
Figure 2. Healthcare Resource Utilization: Number of HCP visits, ER visits, and hospitalizations within the past 6 months: undiagnosed GAD, no-GAD vs diagnosed GAD. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with diagnosed GAD are marked with asterisks. (Abbreviations: GAD: generalized anxiety disorder; HCP: healthcare provider; ER: emergency room.) (Graphic: Business Wire)
Figure 2. Healthcare Resource Utilization: Number of HCP visits, ER visits, and hospitalizations within the past 6 months: undiagnosed GAD, no-GAD vs diagnosed GAD. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with diagnosed GAD are marked with asterisks. (Abbreviations: GAD: generalized anxiety disorder; HCP: healthcare provider; ER: emergency room.) (Graphic: Business Wire)
Figure 3. Health-Related Quality of Life: Scores on Global Health Composite, Mental Health Composite, and Physical Health Composite: GAD by symptom severity vs. controls. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with controls (no-GAD) are marked with asterisks. (Abbreviations: GAD: generalized anxiety disorder; VAS: visual analog scale.) (Graphic: Business Wire)
Figure 3. Health-Related Quality of Life: Scores on Global Health Composite, Mental Health Composite, and Physical Health Composite: GAD by symptom severity vs. controls. Note: Groups that were statistically significant at p0.05, 2-tailed, compared with controls (no-GAD) are marked with asterisks. (Abbreviations: GAD: generalized anxiety disorder; VAS: visual analog scale.) (Graphic: Business Wire)
Business Wire embedded0

Tags

Mental Health
Health
Neurology
Clinical Trials
Pharmaceutical
Biotechnology
ISPOR 2024

More Like This

Business Wire logo

MindMed to Present at Upcoming May Medical Conferences

Business Wire logo

MindMed to Present at Upcoming April Medical Conferences

Business Wire logo

MindMed Presents Phase 2b Study of MM120 for Generalized Anxiety Disorder (GAD) at American Psychiatric Association (APA) Annual Meeting in New York

Business Wire logo

MindMed Awarded Innovation Passport Designation by the United Kingdom (UK) Innovative Licensing and Access Pathway (ILAP) Steering Group for MM120 Orally Disintegrating Tablet (ODT) for Generalized Anxiety Disorder (GAD)

Business Wire logo

MindMed Reports First Quarter 2024 Financial Results and Business Updates

Business Wire logo

MindMed Receives FDA Breakthrough Therapy Designation and Announces Positive 12-Week Durability Data From Phase 2B Study of MM120 for Generalized Anxiety Disorder

Business Wire logo

MindMed Announces Positive Topline Results from Phase 2b Trial of MM-120 in Generalized Anxiety Disorder

Business Wire logo

MindMed Announces Business Update and Anticipated Milestones for 2024